Literature DB >> 22487859

Laforin and malin deletions in mice produce similar neurologic impairments.

Ana M García-Cabrero1, Ainhoa Marinas, Rosa Guerrero, Santiago Rodríguez de Córdoba, José M Serratosa, Marina P Sánchez.   

Abstract

Lafora disease is a progressive myoclonus epilepsy caused by mutations in the EPM2A gene encoding laforin or in the EPM2B gene encoding malin. It is characterized by the presence of polyglucosan intracellular inclusion bodies (Lafora bodies) in brain and other tissues. Targeted disruption of Epm2a or Epm2b genes in mice produced widespread neuronal degeneration and accumulation of Lafora bodies in neuronal and nonneuronal tissues. Here we analyzed the neurologic alterations produced by disruption of the laforin gene in Epm2a mice and compared them to those in malin-deficient mice. Both Epm2a and Epm2b mice showed altered motor activity, impaired motor coordination, abnormal hind limb clasping, and episodic memory deficits. Epm2a mice also had tonic-clonic seizures, whereas both Epm2a and Epm2b mice had spontaneous single spikes, spike-wave, polyspikes, and polyspike-wave complexes with correlated myoclonic jerks. Neurologic alterations observed in the mutants were comparable and correlated with the accumulation of abundant Lafora bodies in the cerebral cortex, the hippocampus, the basal ganglia, the cerebellum, and the brainstem, suggesting that these inclusions could cause cognitive and behavioral deterioration. Thus, both Epm2a and Epm2b mice exhibit many pathologic aspects seen in patients with Lafora disease and may be valuable for the study of this disorder.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487859     DOI: 10.1097/NEN.0b013e318253350f

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  21 in total

Review 1.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

2.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

3.  Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model.

Authors:  Belén Mollá; Miguel Heredia; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2021-01-14       Impact factor: 5.590

Review 4.  The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Paola Lenzi; Alessandro Frati; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2014-09-14       Impact factor: 3.575

5.  The developmental evolution of the seizure phenotype and cortical inhibition in mouse models of juvenile myoclonic epilepsy.

Authors:  Fazal Arain; Chengwen Zhou; Li Ding; Sahar Zaidi; Martin J Gallagher
Journal:  Neurobiol Dis       Date:  2015-06-06       Impact factor: 5.996

6.  Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.

Authors:  Gentzane Sánchez-Elexpuru; José M Serratosa; Marina P Sánchez
Journal:  Epilepsia       Date:  2017-01-18       Impact factor: 5.864

Review 7.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

8.  4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.

Authors:  Gentzane Sánchez-Elexpuru; José M Serratosa; Pascual Sanz; Marina P Sánchez
Journal:  Neuroreport       Date:  2017-03-22       Impact factor: 1.837

9.  Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome.

Authors:  Juan Arranz; Elisa Balducci; Krisztina Arató; Gentzane Sánchez-Elexpuru; Sònia Najas; Alberto Parras; Elena Rebollo; Isabel Pijuan; Ionas Erb; Gaetano Verde; Ignasi Sahun; Maria J Barallobre; José J Lucas; Marina P Sánchez; Susana de la Luna; Maria L Arbonés
Journal:  Neurobiol Dis       Date:  2019-03-01       Impact factor: 5.996

10.  Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.

Authors:  Priyanka Sinha; Bhupender Verma; Subramaniam Ganesh
Journal:  Mol Neurobiol       Date:  2020-10-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.